Sony Biotechnology Inc. Sony Biotechnology Inc.cart
About Us Products What's New Library News Calendar Contact Us Place Order
Safety Data Sheet (SDS) PerCP/Cy55 Anti-mouse IL-4 Antibody     Product Data Sheet (PDF)    
PerCP/Cy5.5 Anti-mouse IL-4 Antibody
3120615 25 µg $115.00       
3120620 100 µg $280.00       
Clone: 11B11
Isotype: Rat IgG1, κ
Reactivity: Mouse
Immunogen: Partially purified native mouse IL-4
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application:

ICFC - Quality tested

Application Notes:

ELISA1,2,10,13 or ELISPOT5 Capture: The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody as the detecting antibody and recombinant mouse IL-4 as the standard.

Recommended Usage:

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application References:

1. Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut)
2. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut)
3. Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097.
4. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISA Capture)
6. Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC)
7. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
8. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
9. Hara M, et al. 2001. J. Immunol. 166:3789. (Neut)
10. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
11. Lawson BR, et al. 2007. J. Immunol. 178:5366.
12. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut)
13. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
14. Ohnmacht C, et al. 2008. Blood 113:2816. PubMed
15. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
16. Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)

Th2-polarized cells from C57BL/6 mouse

Th2-polarized cells from C57BL/6 mouse T cells were stimulated with anti-CD3 and anti-CD28 for 6 hours (in presence of brefeldin A). The cells were then stained with CD3 FITC and subsequently fixed, permeabilized, and stained with IL-4 (clone 11B11) PerCP/Cy5.5 (top) or rat IgG1, κ PerCP/Cy5.5 isotype control (bottom).





Description:

IL-4 is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. IL-4 is a potent lymphoid cell growth factor which stimulates the growth and activation of certain B cells and T cells. IL-4 is important for regulation of T helper subset development.

Other Names: Interleukin-4, Ia inducing factor (IaIF), B cell stimulating factor-1 (BSF-1), Hodgkin's cell growth factor (HCGF), Mast cell growth factor-2 (MCGF-2), Macrophage fusion factor (MFF), T cell growth factor-2 (TCGF-2)
Structure: Cytokine; 15-19 kD (Mammalian)
Regulation: Upregulated by IL-2, platelet activating factor; downregulated by TGF-β
Cellular Sources: Mast cells, T cells, bone marrow stromal cells
Cellular Targets: B cells, T cells, monocytes, endothelial cells, fibroblasts
Receptors: Heterodimer IL-4Rα (CD124); γ-subunit (CD132) in common with IL-2R, IL-7R, IL-13R, IL-15R
Bioactivity/Activities: Differentiation of naïve CD4+ T cells to the TH2 type, proliferation/differentiation of activated B cells, expression of class II MHC antigens, and of low affinity IgE receptors in resting B cells
Antigen References:

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Boulay J, et al. 1992. Curr. Opin. Immunol. 4:294.
3. Dullens H, et al. 1991. In vivo 5:567.
4. Paul W. 1991. Blood 77:1859.


This product or portions thereof is manufactured under license from GE Healthcare under U.S. Patent Numbers 5,268,486; 5,569,587; 5,627,027 and patents or pending applications that are continuations, continuations-in-part, re-examinations, divisionals, reissues or foreign equivalents thereof. THIS MATERIAL IS SUBJECT TO PROPRIETARY RIGHTS OF GE HEALTHCARE BIO-SCIENCES CORP. AND CARNEGIE MELLON UNIVERSITY AND MADE AND SOLD UNDER LICENSE FROM GE HEALTHCARE BIO-SCIENCES CORP. THIS PRODUCT IS LICENSED FOR SALE ONLY FOR RESEARCH. IT IS NOT LICENSED FOR ANY OTHER USE. THERE IS NO IMPLIED LICENSE HEREUNDER FOR ANY COMMERCIAL USE.
COMMERCIAL USE shall include:

  • sale, lease, license or other transfer of the material or any material derived or produced from it;
  • sale, lease, license or other grant of rights to use this Material or any material derived or produced from it;
  • use of this material to perform services for a fee for third parties.

IF YOU REQUIRE A COMMERCIAL LICENSE TO USE THIS MATERIAL AND DO NOT HAVE ONE RETURN THIS MATERIAL, UNOPENED TO Sony Biotechnology Inc., 2100 South Oak Street, Champaign, IL 61820, USA AND ANY MONEY PAID FOR THE MATERIAL WILL BE REFUNDED.